Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction Act
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.